Nyas_1434007.dvi
Endometriosis and Infertility
Epidemiology and Evidence-based Treatments
EBIHA OZKAN,a WILLIAM MURK,b AND AYDIN ARICI
aDepartment of Obstetrics and Gynecology, Kocaeli University School of Medicine,
bDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University
School of Medicine, New Haven, Connecticut 06520, USA
Endometriosis is an estrogen-dependent disorder defined as the presence of endometrial tis-
sue outside of the uterine cavity. A leading cause of infertility, endometriosis has a prevalence
of 0.5–5% in fertile and 25–40% in infertile women. The optimal choice of management for
endometriosis-associated infertility remains obscure. Removal or suppression of endometrial
deposits by medical or surgical means constitutes the basis of endometriosis management. Cur-
rent evidence indicates that suppressive medical treatment of endometriosis does not benefit
fertility and should not be used for this indication alone. Surgery is probably efficacious for
all stages of the disease. Controlled ovarian hyperstimulation with intrauterine insemination
is recommended in early-stage and surgically corrected endometriosis when pelvic anatomy is
normal. In advanced cases, in vitro fertilization is a treatment of choice, and its success may
be augmented with prolonged gonadotropin-releasing hormone analog treatment. Further ran-
domized clinical trials focusing on diverse etiopathogenic mechanisms and therapeutic innova-
tion are necessary to find more conclusive, evidence-based answers regarding this enigmatic
disease.
Key words: endometriosis; infertility; epidemiology; evidence-based treatments
sis improve fertility? What course of treatment is mostsuitable for a subfertile woman presenting with en-
Infertility is a distressing and frustrating symptom
dometriosis? Answers to these questions will define the
associated with endometriosis, and the optimal choice
primary scope of this review, but first we provide a brief
of management in the context of this disease remains
overview of the epidemiology of this perplexing disease
obscure. Endometriosis, defined as the presence of en-
and its relationship to infertility.
dometrial tissue outside the uterine cavity, is in itself anenigmatic and multifaceted pathology, a puzzle whose
manifold pieces remain largely disconnected despitesome decades of investigation. Although infertility and
endometriosis are clearly connected, uncertainty per-
The true prevalence of endometriosis remains ob-
sists over the causal relation between the two.
scure. Variations in patient populations, methods and
It is somewhat easy to understand how moderate–
criteria of diagnosis, and an overall lack of well-
severe endometriosis is associated with infertility, as it
designed epidemiologic studies have made it difficult
is a destructive disorder that results in considerable
to arrive at confident figures for this disease. Estimates
pain and anatomical distortion of pelvic organs.1
,2 Yet
of prevalence range up to 10% among the general pop-
it is less clear how mild–minimal endometriosis might
ulation,9 and large-scale studies suggest a prevalence
impair fertility without pelvic distortion,3–5 although
of 0.5–5% in fertile and 25–40% in infertile women.10
a number of theories exist.6–8 To what extent can the
Other studies quote figures of 5–50% among the infer-
treatment of the clinical manifestations of endometrio-
tile population,11 and it has been reported that infertilewomen are 6–8 times more likely than fertile womento have the disease.12 A review by D'Hooghe
et al.
Address for correspondence: Aydin Arici, M.D., Department of Ob-
concluded that the prevalence of endometriosis is sig-
stetrics, Gynecology & Reproductive Sciences, Yale University School of
nificantly higher in infertile than fertile women, and
Medicine, 333 Cedar Street, New Haven, CT 06520-8063. Voice: +1-203-785-4018; fax: +1-203-785-7134.
that infertile women are more likely to have advanced
stages of the disease.13
Ann. N.Y. Acad. Sci. 1127: 92–100 (2008). C
2008 New York Academy of Sciences.
Ozkan et al.: Endometriosis-associated Infertility
to altered risk of endometriosis. Smoking has been
A growing body of evidence suggests that age, ge-
found to create a hypoestrogenic state inversely re-
netic factors, menstrual parameters, anthropometric
lated with endometriosis,21 but others have found no
measures, body habitus, lifestyle factors, environmen-
association.16 Increased caffeine and alcohol consump-
tal exposures, and a number of other characteristics
tion has been associated with increased risk, whereas
may play roles in the etiopathogenetic mechanisms of
regular exercise reduces the risk of endometriosis.26
Although Signorello
et al. did not find any relation-
Endometriosis can be identified in women from
ship to alcohol or smoking, they confirmed that exer-
premenarche to postmenopause, and diagnoses have
cising more than 4 h per week decreases the risk of
been made in women ranging from 12 to 80 years of
age. Regardless, endometriosis is foremost a disease of
Exposure to polychlorinated biphenyl (PCB) and
reproductive-age women, which may be explained by
dioxin has been associated with endometriosis in stud-
the estrogenic milieu strongly implicated in its patho-
ies with rhesus monkeys, possibly through effects on the
genesis, and it carries an average age of diagnosis of
immune system.28 In humans, studies of toxin exposure
28 years.14 A positive correlation between age and risk
as measured by serum levels have been contradictory.
of the disease has been noted, particularly at ages above
Positive associations of PCB congeners, heavy metals,
30 and peaking in the early-to-mid 40s.15
,16
chlorinated pesticides, and dioxin with endometriosis
A genetic predisposition to endometriosis has been
have been reported,29 although other studies found no
supported by the high concordance of the disease
association with organic pollutants,30 or found only
among identical twins.17 A familial predisposition
a nonsignificant doubling of risk with dioxin.31
In utero
with no clear Mendelian inheritance, but rather with
exposures may also determine a woman's risk of having
multifactorial polygenic traits, has been identified
endometriosis. Greater birth weight and breast-feeding
in severe endometriosis,4 and a number of genetic
were found to decrease endometriosis risk, while di-
polymorphisms have been investigated.18
,19 Although
ethylstilbestrol exposure and multiple pregnancies in-
Chatman
et al. reported that there is no known racial or
socioeconomic bias for the disease,20 it has been sug-
Despite the fact that little is definitely known re-
gested that Asian women are at higher risk than other
garding the epidemiology of endometriosis, risk fac-
races, with Black women at lower risk.16
,21 However,
tors for the disease appear to be related to increased
this latter finding was attributed to a frequent misdiag-
exposure to menstruation and body estrogen levels.
nosis of Black women as having pelvic inflammatory
Further epidemiologic research is required to establish
disease rather than endometriosis.22
new insights with respect to the etiopathogenesis of this
Menstrual and reproductive factors associated with
puzzling disorder.
increased risk of endometriosis include early menarche(≤11 years of age), short menstrual cycles (≤27 days),
Endometriosis and Infertility
heavy and long-lasting bleeding, reduced parity, and
Although endometriosis is generally accepted to
reduced lifetime duration of lactation.11
,22
,23 Cramer
be related to infertility, its actual impact on fecundity
and Missmer proposed a possible endometriosis phe-
and the mechanisms underlying this effect are less
notype of early menarche, short cycles, painful periods,
clear. Unfortunately, well-designed scientific studies
subfertility, and tall stature.11
are lacking on this issue.33 Fecundity, defined as the
Taller and thinner women appear to have en-
probability of a woman achieving a live birth in a
dometriosis more frequently, consistent with higher
given month, ranges from 0.15 to 0.20 in normal
follicular-phase estradiol levels in taller women. Body
couples and 0.02 to 0.10 in untreated women with
weight, body mass index, and waist-to-hip ratio have
endometriosis.34–36 Significantly lower 3-year cumu-
been inversely correlated with endometriosis,22 al-
lative conception rates in women with endometriosis
though Missmer
et al. did not find a relation with waist-
compared with controls (36% vs. 54%),37 and reduced
to-hip ratio.21 Interestingly, women with naturally red
conception rates in women with endometriosis who
hair may have an increased risk of endometriosis, pos-
had donor inseminations to control for male and
sibly associated with altered coagulation and immune
coital factors have consistently shown a relation
functions.24 Missmer
et al. found no association with
between decreased fertility and endometriosis.38 A
red hair, although they concluded that this may de-
variety of animal and human studies, including those
pend on infertility status.25
involving assisted reproductive technology (ART),
Lifestyle factors, such as smoking, exercise, and con-
have also suggested lower pregnancy rates in cases of
sumption of alcohol and caffeine, have been related
endometriosis.39 A meta-analysis by Barnhart
et al.
Annals of the New York Academy of Sciences
reported an endometriosis pregnancy rate that is half
rupted pelvic anatomy have been reported to have
that for tubal factor infertility.40
pregnancy rates near 0%; this disparity in fecundity
Experience from IVF has indicated poor pregnancy
between stages of endometriosis may confound the in-
outcomes in endometriosis patients are associated with
terpretation of various therapeutic modalities.
poor sperm function, poor ovarian reserve, reducedoocyte retrieval, lower oocyte and embryo quality, im-
Medical Treatment of
paired implantation with decreased endometrial re-
ceptivity, and luteinized unruptured follicles, particu-
Medical treatment of endometriosis typically in-
larly in advanced-stage disease.41–43 However, contra-
volves hormonal manipulation of the menstrual cycle
dictory studies exist.44–46 ART outcomes in patients
to create an amenorrheic state, thus producing an en-
with endometriosis are also contradictory, with some
vironment unfavorable to endometrial tissue. Dana-
reporting decreased numbers of preovulatory follicles,
zol, progestational drugs, gestrinone, oral contracep-
reduced embryo transfers, decreased fertility rates, and
tives, and gonadotropin-releasing hormone (GnRH)
increased miscarriages,47 whereas others suggest sim-
agonists (GnRHa) are conventionally used medical
ilar results with control cases.48 Additionally, adverse
agents. In addition, experimental medications, such as
pregnancy outcomes, such as pregnancy loss, preterm
selective estrogen receptor modulators, selective pro-
delivery, preeclampsia, and intrauterine growth restric-
gesterone receptor modulators, aromatase inhibitors,
tion, have been demonstrated to occur more frequently
GnRH antagonists, pentoxifylline, tumor necrosis
in subjects with endometriosis.49
factor-α inhibitors, angiogenesis inhibitors, and ma-trix metalloproteinase inhibitors, hold the potential forgreater efficacy and flexibility with fewer side effects.
Evidence-based Management in
Evidence to date indicates that medical therapy is
not of benefit for endometriosis-associated infertility. Acomprehensive 2007 Cochrane review by Hughes
et al.
Primary aims of endometriosis treatment are the re-
examining 24 randomized controlled trials (RCTs) con-
moval or reduction of ectopic endometrial implants,
cluded that pregnancy outcomes did not improve from
restoration of normal anatomy, hindrance of disease
treatment with ovulation-suppression agents (includ-
progression, and alleviation of symptoms. A broad
ing danazol, GnRHa, medroxyprogesterone, gestri-
spectrum of therapeutic options, including expectant
none, and oral contraceptives) compared to placebo
management, medical and surgical interventions alone
(odds ratio [OR]: 0.79, 95% confidence interval [CI]:
or in combination, and ART, have been used to address
0.54–1.14,
P = 0.21) or no treatment (OR: 0.80, 95%
the clinical sequelae of endometriosis.2
,50
,51 However,
CI: 0.51–1.24,
P = 0.32), and that none of the med-
the efficacy of these options with regard to achieving
ical agents was more efficacious or better than any
conception success in endometriosis-associated infertil-
other.36 These drugs merely serve to delay fertility in-
ity is considerably variable and remains inadequately
stead of increasing pregnancy rates; further, they are,
explored, as reviewed below.
in themselves, detrimental for fecundity and carry sig-nificant costs and side effects. Therefore, they should
Expectant Management
be discouraged in the management of endometriosis-
In spite of a significantly impaired pregnancy rate in
associated infertility, with the possible exception of use
comparison with the general population, patients with
in
in vitro fertilization (IVF). European Society of Hu-
early-stage endometriosis without severe pelvic adhe-
man Reproduction and Embryology (ESHRE) guide-
sions are able to conceive spontaneously. A prospec-
lines for the treatment of endometriosis-associated in-
tive multicenter cohort study assessing 168 patients
fertility state that hormonal suppression of ovarian
with endometriosis undergoing expectant manage-
function does not improve fertility in minimal–mild
ment found that the monthly fecundity rate of 2.52
or more severe endometriosis, and should not be of-
per 100 person-months did not differ significantly from
fered for this reason alone (recommendation grade A,
the fecundity of 263 women with unexplained infertil-
evidence level 1a).57
ity.52 Other studies have found monthly fecundity rates
Experimental medications that do not inhibit ovu-
ranging between 0.14 and 0.45.53–55 Hull
et al. reported
lation can be used without a delay of attempted
a cumulative pregnancy rate of 55% in 56 cases of
conception. Pentoxifylline is a phosphodiesterase in-
minimal–mild endometriosis after an expectant man-
hibitor with anti-inflammatory properties and has
agement of 18 months.56 However, cases of advanced-
been investigated in infertile women with endometrio-
stage endometriosis complicated with extremely dis-
sis. A single small-scale RCT with 60 cases reported
Ozkan et al.: Endometriosis-associated Infertility
a nonsignificant increase in pregnancy rates with
that a structural normalization of severely distorted
pentoxifylline use (31% vs. 18.5% with placebo in a
pelvic anatomy can improve conception outcomes,
12-month period),58 whereas a prospective, double-
as supported by the above studies. Future RCTs are
blind, randomized, placebo-controlled study did not
needed to reach definitive answers on the efficacy of
find any fertility improvement with the same med-
surgery in advanced endometriosis.
ication.59 This latter study concluded that pentoxi-fylline did not enhance fertility or lessen recurrence
in any stage of endometriosis. Other emerging drugs
The value of surgical treatment in minimal–mild en-
that do not suppress ovarian function and instead
dometriosis is more controversial. In a Canadian RCT
selectively target endometriotic lesions may yet hold
of 341 infertile women (20–39 years of age) with stage
promise, but current evidence based on the established
I–II disease, 169 underwent diagnostic laparoscopy
pharmacopoeia indicates that medical treatment of
with no treatment and 172 underwent operative la-
endometriosis-associated infertility is not effective and
paroscopy with ablation or excision of endometrial
should not be pursued.
implants. Subjects were followed up for 36 weeks post-operatively and for up to 20 weeks of gestation if they
Surgical Treatment in
conceived.54 The cumulative pregnancy rates and fe-
cundity rates were found to be significantly higher in
Restoration of disrupted pelvic anatomy is the main-
surgically managed patients (30.7% vs. 17.7% for those
stay of surgical treatment of endometriosis-associated
with no treatment, OR: 1.7, CI: 1.2–2.6 and 4.7% vs.
infertility and involves the destruction of endometriotic
2.4%, OR: 1.9, CI: 1.2–3.1, respectively). There was
deposits, removal of endometriomas, and adhesiolysis.
no evidence that outcomes were affected by method
Laparotomy and laparoscopy are efficacious routes of
of ablation by electrosurgery or laser delivery systems.
access for surgery, but laparoscopy has shorter hospi-
However, contradictory conclusions were made by an
talization, recovery, and return-to-work times, fewer
Italian study, which involved a similar design but exam-
adhesions, and greater patient comfort.60
,61 Surgery is
ined a smaller number of early-stage patients (
n = 101),
usually the treatment of choice to restore disrupted
and followed pregnancies 1 year after laparoscopic in-
pelvic anatomy and remove endometriomas in ad-
tervention proceeding to live births.68 Live birth rates
vanced stages,62
,63 whereas the question of optimal
were comparable in surgically treated and nontreated
treatment remains more controversial in early stages
subjects (19.6% vs. 22.2%, respectively). Neither of
of the disease without anatomical distortion.
these studies was free of confounding factors. In theCanadian study, subjects were informed about the ran-
Advanced Endometriosis
domization, 10% of women in each group received
Although few RCTs have examined the efficacy of
fertility treatment or adhesiolysis, pregnancy rates in
surgical approaches in advanced endometriosis, some
control cases were lower than expected, the follow-up
evidence indicates that surgery can be of value. Sev-
period was less than 1 year, no distinction was made be-
eral nonrandomized trials involving cases of severe en-
tween active red lesions and nonactive black or fibrotic
dometriosis have found a rise in pregnancy rates after
white lesions, vascularization and mitotic activity were
reparative surgery compared with rates of approxi-
not taken into account, and mapping of lesions was
mately 0% in untreated cases.64
,65 A meta-analysis of
not considered in the selection at the time. The Italian
one quasi-randomized and five cohort studies reported
study had a lower statistical power because its series
that surgery may be of value to improve pregnancy
was small (
n = 54 operative surgeries vs.
n = 47 diag-
rates compared with no treatment or medical therapy,
nostic laparoscopies), with patients distributed among
but the heterogeneity of these studies unfortunately re-
seven different centers. The patients had a longer du-
duces the confidence of such a conclusion.35 Moreover,
ration of infertility and slightly more extensive disease;
two prospective randomized studies by Busacca
et al.
histologic confirmation was not requested; rates of
and Soong
et al. concluded that operative laparoscopy
red, white, or black lesions were not recorded; and
was beneficial for infertile women with advanced-stage
vascularization and mitotic activity were not consid-
endometriosis, although the latter study found a re-
ered. Regardless, a meta-analysis of these two studies
duced postoperative conception rate in women with
concluded that surgery was of significant benefit in
stage IV compared with stage III disease.66
,67 ESHRE
infertile patients with early-stage endometriosis (OR:
guidelines state that data are insufficient regarding the
1.7, 95%, CI: 1.1–2.5).69 However, the degree of the
efficacy of surgical treatment in cases of moderate–
conferred benefit appears to be small: the number of
severe endometriosis.57 Regardless, it seems intuitive
women who must undergo surgery to achieve a single
Annals of the New York Academy of Sciences
additional pregnancy in these cases has been calcu-
tive than expectant management in improving fertility
lated as 7.7, which may be unacceptably high for some
for endometriosis-associated infertility (recommenda-
patients. ESHRE guidelines state that endometriotic
tion grade A, evidence level 1b).57
,75
,77–79
lesion ablation with adhesiolysis improves fertility in
Thus, it appears that no qualified evidence indicates
minimal–mild endometriosis compared with diagnos-
that fertility is enhanced by combination surgery with
tic laparoscopy alone (recommendation grade A, evi-
either preoperative or postoperative medical therapy,
dence level 1a).57
,70
and the conversion of theoretical advantages into prac-tical outcomes has hitherto been unfruitful. As with
Combined Medical and Surgical Therapies
medical treatment alone, medication combined with
in Endometriosis-associated Infertility
surgery may only serve to delay fertility.
Surgery combined with pre- and postoperative med-
ical therapy represents a growing field of drug appli-
Assisted Reproductive Technologies
cation. Theoretically, preoperative medication may re-
in Endometriosis-associated Infertility
duce inflammation, vascularization, and implant size,
Controlled Ovarian Hyperstimulation With or
making for faster, easier, less traumatic surgery, with
Without Intrauterine Insemination
the possibility of surgical scheduling in any time of
A number of randomized trials assessing the ef-
cycle and the potential for complete eradication of
ficacy of ovulation induction with or without in-
the disease and decreased risk of postoperative ad-
trauterine insemination (IUI) have found that ovu-
hesions. However, drawbacks of combined therapy in-
lation induction enhances fertility rates in cases of
clude drug costs, side effects, and temporary regression
endometriosis-associated infertility without distorted
of endometrial foci allowing escape from laparoscopic
pelvic anatomy or male factor infertility.4
,53
,80–82
recognition and ablation.
Guzick compared fecundity rates after randomizingpatients into intracervical insemination (ICI), IUI,
Preoperative Medical Therapy
gonadotropin induction/ICI, and gonadotropin in-
The preoperative use of medication may be useful
duction/IUI.83 Monthly fecundity rates were high-
for reducing the severity of endometriosis. A prospec-
est in the gonadotropin induction/IUI group (0.09),
tive multicenter clinical trial by Audebert
et al. re-
followed by IUI (0.05), gonadotropin induction/ICI
ported reductions in severity with preoperative com-
(0.04), and ICI (0.02). A study by Adamson
et al. re-
pared with postoperative GnRHa treatment, although
ported that monthly fecundity in infertile couples with
surgical feasibility did not differ significantly.71 Nasal
endometriosis was doubled with clomiphene citrate to
application of GnRHa has revealed decreased inflam-
approximately 7% per month, and quadrupled with
mation, vascularization, severity, and endometrioma
menotropins to 15%, compared with no treatment.84
growth,72 and a study by Muzii
et al. found that preop-
However, RCTs assessing superovulation with IUI in
erative GnRHa can improve surgical performance.73
advanced-stage endometriosis are lacking. ESHRE
However, in the absence of convincing evidence of im-
guidelines conclude that IUI with ovarian stimulation
provements in surgical feasibility and in fertility rate,
improves fertility in minimal–mild endometriosis, but
preoperative medication appears to be unjustified, as
the effect of unstimulated IUI is not clear (recommen-
the theoretical benefits do not seem to outweigh the
dation grade A, evidence level 1b).57
,81 It is important
increased costs and rates of morbidity.
to note that, because ovarian stimulation may lead tothe progression of ovarian endometriosis, controlled
Postoperative Medical Therapy
ovarian hyperstimulation (COH) with IUI should be
Postoperative medical therapy is another option in
limited to a maximum of three to four cycles, and IVF-
combined therapy, aiming to achieve resorption of
embryo transfer should be preferred.85
residual deposits that cannot be surgically removed,destruction of microscopic implants, and reduction of
Assisted Reproductive Technologies
disease dissemination in case of endometrioma rup-
in Endometriosis-associated Infertility
ture. Three studies have evaluated the use of postopera-
The impact of endometriosis on IVF outcomes re-
tive medical therapy with GnRHa and raloxifene,74–76
mains uncertain. Some studies have reported IVF
and other randomized trials have examined postopera-
success rates in cases of endometriosis comparable
tive ovarian suppression.73–75
,77–79 None of these stud-
with those of unexplained or tubal factor infertil-
ies reported increased fertility rates with postoperative
ity48
,86
,87 or improved outcomes with increasing dis-
medication. ESHRE guidelines conclude that postop-
ease stage,41 whereas other studies have found re-
erative danazol or GnRHa treatment is not more effec-
duced success rates.1
,43
,88 These inconsistent results
Ozkan et al.: Endometriosis-associated Infertility
may be attributable to laparoscopic oocyte retrieval
rent medical therapy is not efficacious, and its use
and inferior laboratory methodologies used in early
should be discouraged as it may only serve to post-
studies.4 A meta-analysis involving 22 nonrandomized
pone conception. Laparoscopic surgery appears to be
studies of IVF outcome found lower pregnancy rates in
superior to expectant management or medical ther-
patients with endometriosis compared with those with
apy in minimal–mild endometriosis and may also be
tubal factor infertility; it was reported that women with
of benefit for patients with advanced endometriosis.
severe endometriosis were less likely to achieve preg-
The quality of available evidence supporting the use
nancy success than those with mild disease.40 Reduced
of preoperative or postoperative medication combined
oocyte retrieval, fertilization, and implantation rates
with surgery is too poor to make a recommendation
were also associated with endometriosis, and it has
on such regimens. COH/IUI is a good option in mild
been suggested that lower implantation rates in en-
and surgically corrected disease. In patients with early-
dometriosis may be attributable to diminished ovarian
stage endometriosis, IVF outcomes are similar to those
reserve rather than embryo quality or uterine receptiv-
with unexplained or tubal factor infertility, and Gn-
ity.89 An analysis of the Human Fertilisation and Em-
RHa treatment combined with IVF may be useful for
bryology Authority database suggested that IVF live
more advanced disease.
birth rates are not adversely affected by endometriosis
Further RCTs with rigorous scientific designs are
compared with unexplained infertility.90 No evidence
needed to establish a comprehensive evidence-based
shows adverse effects of endometriosis on implantation
approach to deciding among management strategies
and pregnancy rates in patients undergoing intracyto-
for endometriosis-associated infertility.
plasmic sperm injection.91
Several studies suggest that long-term treatment
Conflicts of Interest
with GnRHa before IVF may improve fertility rates inadvanced-stage endometriosis by means of increased
The authors declare no conflicts of interest.
numbers of retrieved oocytes and transferred em-bryos, higher implantation and pregnancy rates, and
reduced rates of preclinical abortions.92
,93 ESHREguidelines recommend that IVF treatment is suitable
1. OLIVE, D.L. & E.A. PRITTS. 2001. Treatment of endometrio-
for endometriosis-associated infertility, particularly for
sis. N. Engl. J. Med.
345: 266–275.
cases involving impaired tubal function, male factor
2. CAHILL, D.J. 2002. What is the optimal medical manage-
ment of infertility and minor endometriosis? Analysis and
infertility, and/or failure of other treatments (recom-
future prospects. Hum. Reprod.
17: 1135–1140.
mendation grade B, evidence level 2b).57 Moreover,
3. GORDTS, S.
et al. 2003. Endometriosis: modern surgical
endometriosis is associated with lower IVF pregnancy
management to improve fertility. Best Pract. Res. Clin.
rates than tubal infertility (recommendation grade A,
Obstet. Gynaecol.
17: 275–287.
evidence level 1a).57
,40
4. BUYALOS, R.P. & S.K. AGARWAL. 2000. Endometriosis-
Finally, prolonged GnRHa treatment prior to IVF
associated infertility. Curr. Opin. Obstet. Gynecol.
12:
should be considered for cases of moderate–severe en-
5. SURREY, E.S. & W.B. SCHOOLCRAFT. 2003. Management
dometriosis, as it has been associated with increased
of endometriosis-associated infertility. Obstet. Gynecol.
pregnancy rates (recommendation grade A, evidence
Clin. North Am.
30: 193–208.
6. HALIS, G. & A. ARICI. 2004. Endometriosis and inflamma-
tion in infertility. Ann. N.Y. Acad. Sci.
1034: 300–315.
7. MAHUTTE, N.G. & A. ARICI. 2002. New advances in the un-
derstanding of endometriosis related infertility. J. Reprod.
Immunol.
55: 73–83.
Beset with inadequate, inconclusive, and conflicting
8. MULAYIM, N. & A. ARICI. 1999. The relevance of the peri-
data, it remains difficult to arrive at a consensus regard-
toneal fluid in endometriosis-associated infertility. Hum.
ing appropriate choices of treatment for endometriosis-
Reprod.
14(Suppl 2): 67–76.
associated infertility. Even so, the current evidence does
9. ESKENAZI, B. & M.L. WARNER. 1997. Epidemiology of en-
allow for a number of conclusions to be drawn.
dometriosis. Obstet. Gynecol. Clin. North Am.
24: 235–
Despite the lack of a firmly established causal rela-
tion between endometriosis and infertility, it is clear
10. HOUSTON, D.E.
et al. 1987. Incidence of pelvic endometriosis
in Rochester, Minnesota, 1970–1979. Am. J. Epidemiol.
that treatment of endometriosis can improve fertil-
ity in some cases. Expectant management may be a
11. CRAMER, D.W. & S.A. MISSMER. 2002. The epidemiology
reasonable approach in younger patients with early-
of endometriosis. Ann. N.Y. Acad. Sci.
955: 11–22; dis-
stage disease and a shorter duration of infertility. Cur-
cussion 34–6, 396–406.
Annals of the New York Academy of Sciences
12. VERKAUF, B.S. 1987. Incidence, symptoms, and signs of
34. THE PRACTICE COMMITTEE OF THE AMERICAN SOCIETY
endometriosis in fertile and infertile women. J. Fla. Med.
FOR REPRODUCTIVE MEDICINE. 2004. Endometriosis and
Assoc.
74: 671–675.
infertility. Fertil. Steril.
81: 1441–1446.
13. D'HOOGHE, T.M.
et al. 2003. Endometriosis and subfertility:
35. HUGHES, E.G.
et al. 1993. A quantitative overview of con-
is the relationship resolved? Semin. Reprod. Med.
21:
trolled trials in endometriosis-associated infertility. Fertil.
Steril.
59: 963–970.
14. PRITTS, E.A. & R.N. TAYLOR. 2003. An evidence-based eval-
36. HUGHES, E.
et al. 2007. Ovulation suppression for en-
uation of endometriosis-associated infertility. Endocrinol.
dometriosis. Cochrane Database Syst. RevCD000155.
Metab. Clin. N. Am.
32: 653–667.
37. AKANDE, V.A.
et al. 2004. Differences in time to natural con-
15. VESSEY, M.P.
et al. 1993. Epidemiology of endometriosis
ception between women with unexplained infertility and
in women attending family planning clinics. BMJ.
306:
infertile women with minor endometriosis. Hum. Reprod.
16. SANGI-HAGHPEYKAR, H. & A.N. POINDEXTER III. 1995. Epi-
38. BARRATT, C.L.
et al. 1990. Donor insemination—a look to
demiology of endometriosis among parous women. Ob-
the future. Fertil. Steril.
54: 375–387.
stet. Gynecol.
85: 983–992.
39. BERGQVIST, A. & T. D'HOOGHE. 2002. Mini sympo-
17. HADFIELD, R.M.
et al. 1997. Endometriosis in monozygotic
sium on pathogenesis of endometriosis and treatment of
twins. Fertil. Steril.
68: 941–942.
endometriosis-associated subfertility. Introduction: the en-
18. GEORGIOU, I.
et al. 1999. Association of estrogen receptor
dometriosis enigma. Hum. Reprod. Update
8: 79–83.
gene polymorphisms with endometriosis. Fertil. Steril.
72:
40. BARNHART, K.
et al. 2002. Effect of endometriosis on in vitro
fertilization. Fertil. Steril.
77: 1148–1155.
19. VIGANO, P.
et al. 2007. Genetics of endometriosis: current
41. ARICI, A.
et al. 1996. The effect of endometriosis on implan-
status and prospects. Front. Biosci.
12: 3247–3255.
tation: results from the Yale University in vitro fertiliza-
20. CHATMAN, D.L. 1976. Endometriosis and the black woman.
tion and embryo transfer program. Fertil. Steril.
65: 603–
J. Reprod. Med.
16: 303–306.
21. MISSMER, S.A.
et al. 2004. Incidence of laparoscopically con-
42. LESSEY, B.A. 2002. Implantation defects in infertile women
firmed endometriosis by demographic, anthropometric,
with endometriosis. Ann. N.Y. Acad. Sci.
955: 265–280;
and lifestyle factors. Am. J. Epidemiol.
160: 784–796.
discussion 293–295, 396–406.
22. MISSMER, S.A. & D.W. CRAMER. 2003. The epidemiology
43. AZEM, F.
et al. 1999. Patients with stages III and IV en-
of endometriosis. Obstet. Gynecol. Clin. North Am.
30:
dometriosis have a poorer outcome of in vitro fertilization-
1–19, vii.
embryo transfer than patients with tubal infertility. Fertil.
23. MISSMER, S.A.
et al. 2004. Reproductive history and en-
Steril.
72: 1107–1109.
dometriosis among premenopausal women. Obstet. Gy-
44. BURKE, L.M.
et al. 2000. Predictors of success after embryo
necol.
104: 965–974.
transfer: experience from a single provider. Am. J. Obstet.
24. HORNSTEIN, M.D. & R.L. BARBIERI. 1999. Endometrio-
Gynecol.
182: 1001–1004.
sis.
In Kistner's Gynecology and Women's Health. K.J.
45. BURNS, W.N. & R.S. SCHENKEN. 1999. Pathophysiology of
RYAN & R.W. KISTNER, Eds: 492–518. Mosby. St. Louis,
endometriosis-associated infertility. Clin. Obstet. Gynecol.
25. MISSMER, S.A.
et al. 2006. Natural hair color and the inci-
46. DIAZ, I.
et al. 2000. Impact of stage III-IV endometriosis on
dence of endometriosis. Fertil. Steril.
85: 866–870.
recipients of sibling oocytes: matched case-control study.
26. BERUBE, S.
et al. 1998. Characteristics related to the preva-
Fertil. Steril.
74: 31–34.
lence of minimal or mild endometriosis in infertile women.
47. YANUSHPOLSKY, E.H.
et al. 1998. Effects of endometriomas
Epidemiology
9: 504–510.
on ooccyte quality, embryo quality, and pregnancy rates in
27. SIGNORELLO, L.B.
et al. 1997. Epidemiologic determinants
in vitro fertilization cycles: a prospective, case-controlled
of endometriosis: a hospital-based case-control study. Ann.
study. J. Assist. Reprod. Genet.
15: 193–197.
Epidemiol.
7: 267–271.
48. AL-AZEMI, M.
et al. 2000. Ovarian response to repeated
28. RIER, S.E.
et al. 1993. Endometriosis in rhesus monkeys
controlled stimulation in in-vitro fertilization cycles in pa-
(Macaca mulatta) following chronic exposure to 2,3,7,8-
tients with ovarian endometriosis. Hum. Reprod.
15: 72–
tetrachlorodibenzo-p-dioxin. Fundam. Appl. Toxicol.
21:
49. BROSENS, I. 2004. Endometriosis and the outcome of in vitro
29. MAYANI, A.
et al. 1997. Dioxin concentrations in women with
fertilization. Fertil. Steril.
81: 1198–1200.
endometriosis. Hum. Reprod.
12: 373–375.
50. CHILD, T.J. & S.L. TAN. 2001. Endometriosis: aetiology,
30. LEBEL, G.
et al. 1998. Organochlorine exposure and the risk
pathogenesis and treatment. Drugs
61: 1735–1750.
of endometriosis. Fertil. Steril.
69: 221–228.
51. ADAMSON, D. 2003. Surgical management of endometriosis.
31. ESKENAZI, B.
et al. 2002. Serum dioxin concentrations and
Semin. Reprod. Med.
21: 223–234.
endometriosis: a cohort study in Seveso, Italy. Environ.
52. BERUBE, S.
et al. 1998. Fecundity of infertile women with min-
Health Perspect.
110: 629–634.
imal or mild endometriosis and women with unexplained
32. MISSMER, S.A.
et al. 2004. In utero exposures and the inci-
infertility. Fertil. Steril.
69: 1034–1041.
dence of endometriosis. Fertil. Steril.
82: 1501–1508.
53. FEDELE, L.
et al. 1992. Superovulation with human
33. OSUGA, Y.
et al. 2002. Role of laparoscopy in the treatment
menopausal gonadotropins in the treatment of infertility
of endometriosis-associated infertility. Gynecol. Obstet.
associated with minimal or mild endometriosis: a con-
Invest.
53(Suppl 1): 33–39.
trolled randomized study. Fertil. Steril.
58: 28–31.
Ozkan et al.: Endometriosis-associated Infertility
54. MARCOUX, S.
et al. 1997. Laparoscopic surgery in infertile
72. DONNEZ, J.
et al. 1994. Ovarian endometrial cysts: the
women with minimal or mild endometriosis. N. Engl. J.
role of gonadotropin-releasing hormone agonist and/or
Med.
337: 217–222.
drainage. Fertil. Steril.
62: 63–66.
55. ADAMSON, G.D. & D.J. PASTA. 1994. Surgical treatment
73. MUZII, L.
et al. 1996. The impact of preoperative
of endometriosis-associated infertility: meta-analysis com-
gonadotropin-releasing hormone agonist treatment on la-
pared with survival analysis. Am. J. Obstet. Gynecol.
171:
paroscopic excision of ovarian endometriotic cysts. Fertil.
1488–1504; discussion 1504–1505.
Steril.
65: 1235–1237.
56. HULL, M.E.
et al. 1987. Comparison of different treatment
74. HORNSTEIN, M.D.
et al. 1997. Use of nafarelin versus placebo
modalities of endometriosis in infertile women. Fertil.
after reductive laparoscopic surgery for endometriosis. Fer-
Steril.
47: 40–44.
til. Steril.
68: 860–864.
57. KENNEDY, S.
et al. 2005. ESHRE guideline for the diagnosis
75. VERCELLINI, P.
et al. 1999. A gonadotrophin-releasing hor-
and treatment of endometriosis. Hum. Reprod.
20: 2698–
mone agonist compared with expectant management after
conservative surgery for symptomatic endometriosis. Br. J.
58. BALASCH, J.
et al. 1997. Pentoxifylline versus placebo in the
Obstet. Gynaecol.
106: 672–677.
treatment of infertility associated with minimal or mild
76. ALVAREZ-GIL, L. & V. FUENTES. 2002. Raloxifene and en-
endometriosis: a pilot randomized clinical trial. Hum. Re-
dometriosis. Fertil. Steril.
77: S37.
prod.
12: 2046–2050.
77. BUSACCA, M.
et al. 2001. Post-operative GnRH analogue
59. ALBORZI, S.
et al. 2007. Pentoxifylline therapy after la-
treatment after conservative surgery for symptomatic en-
paroscopic surgery for different stages of endometrio-
dometriosis stage III–IV: a randomized controlled trial.
sis: a prospective, double-blind, randomized, placebo-
Hum. Reprod.
16: 2399–2402.
controlled study. J. Minim. Invasive Gynecol.
14: 54–
78. PARAZZINI, F.
et al. 1994. Postsurgical medical treatment of
advanced endometriosis: results of a randomized clinical
60. WINKEL, C.A. 2003. Evaluation and management of
trial. Am. J. Obstet. Gynecol.
171: 1205–1207.
women with endometriosis. Obstet. Gynecol.
102: 397–
79. BIANCHI S.
et al. 1999. Effects of 3 month therapy with dana-
zol after laparoscopic surgery for stage III/IV endometrio-
61. BUSACCA, M.
et al. 1998. Surgical treatment of recurrent
sis: a randomized study. Hum. Reprod.
14: 1335–
endometriosis: laparotomy versus laparoscopy. Hum. Re-
prod.
13: 2271–2274.
80. DEATON, J.L.
et al. 1990. A randomized, controlled trial of
62. CHAPRON, C.
et al. 2002. Management of ovarian endometri-
clomiphene citrate and intrauterine insemination in cou-
omas. Hum. Reprod. Update
8: 591–597.
ples with unexplained infertility or surgically corrected
63. BUSACCA, M. & M. VIGNALI. 2003. Ovarian endometrio-
endometriosis. Fertil. Steril.
54: 1083–1088.
sis: from pathogenesis to surgical treatment. Curr. Opin.
81. TUMMON, I.S.
et al. 1997. Randomized controlled trial of
Obstet. Gynecol.
15: 321–326.
superovulation and insemination for infertility associated
64. AL-INANY, H.G. 2000. Evidence may change with more
with minimal or mild endometriosis. Fertil. Steril.
68: 8–
trials: concepts to be kept in mind. Hum. Reprod.
15:
82. CHAFFKIN, L.M.
et al. 1991. A comparative analysis of the
65. OLIVE, D.L. & K.L. LEE. 1986. Analysis of sequential
cycle fecundity rates associated with combined human
treatment protocols for endometriosis-associated infertil-
menopausal gonadotropin (hMG) and intrauterine insem-
ity. Am. J. Obstet. Gynecol.
154: 613–619.
ination (IUI) versus either hMG or IUI alone. Fertil. Steril.
66. BUSACCA, M.
et al. 1999. Follow-up of laparoscopic treatment
of stage III-IV endometriosis. J. Am. Assoc. Gynecol. La-
83. GUZICK, D.S. 1997. Randomized controlled trial of super-
parosc.
6: 55–58.
ovulation and insemination for infertility associated with
67. SOONG, Y.K.
et al. 1997. Life table analysis of pregnancy rates
minimal or mild endometriosis. J. Womens Health
6: 489–
in women with moderate or severe endometriosis compar-
ing danazol therapy after carbon dioxide laser laparoscopy
84. ADAMSON, G.D. 1997. Treatment of endometriosis-
plus electrocoagulation or laparotomy plus electrocoagu-
associated infertility. Semin. Reprod. Endocrinol.
15:
lation versus danazol therapy only. J. Am. Assoc. Gynecol.
Laparosc.
4: 225–230.
85. DMOWSKI, W.P.
et al. 2002. Cycle-specific and cumulative
68. GRUPPO ITALIANO PER LO STUDIO DELL'ENDOMETRIOSIS.
fecundity in patients with endometriosis who are under-
1999. Ablation of lesions or no treatment in minimal–
going controlled ovarian hyperstimulation-intrauterine in-
mild endometriosis in infertile women: a randomized trial.
semination or in vitro fertilization-embryo transfer. Fertil.
Hum. Reprod.
14: 1332–1334.
Steril.
78: 750–756.
69. OLIVE, D.L. 2002. Endometriosis: does surgery make a dif-
86. TINKANEN, H. & E. KUJANSUU. 2000. In vitro fertilization
ference? OBG Manage.
14: 56–70.
in patients with ovarian endometriomas. Acta Obstet. Gy-
70. JACOBSON, T.Z.
et al. 2002. Laparoscopic surgery for subfer-
necol. Scand.
79: 119–122.
tility associated with endometriosis. Cochrane Database
87. KODAMA, H.
et al. 1996. Benefit of in vitro fertilization treat-
Syst. RevCD001398.
ment for endometriosis-associated infertility. Fertil. Steril.
71. AUDEBERT, A.
et al. 1998. Pre or post-operative medical
treatment with nafarelin in stage III–IV endometriosis:
88. GARRIDO, N.
et al. 2000. Follicular hormonal environment
a French multicenter study. Eur. J. Obstet. Gynecol. Re-
and embryo quality in women with endometriosis. Hum.
prod. Biol.
79: 145–148.
Reprod. Update
6: 67–74.
Annals of the New York Academy of Sciences
89. MATALLIOTAKIS, I.M.
et al. 2007. Women with advanced-
92. SURREY, E.S.
et al. 2002. Effect of prolonged gonadotropin-
stage endometriosis and previous surgery respond less well
to gonadotropin stimulation, but have similar IVF implan-
come of in vitro fertilization-embryo transfer in pa-
tation and delivery rates compared with women with tubal
tients with endometriosis. Fertil. Steril.
78: 699–
factor infertility. Fertil. Steril.
88: 1568–1572.
90. TEMPLETON, A.
et al. 1996. Factors that affect outcome of
93. OLIVENNES, F.
et al. 1995. Endometriosis: a stage by stage
in-vitro fertilisation treatment. Lancet
348: 1402–1406.
analysis—the role of in vitro fertilization. Fertil. Steril.
64:
91. BUKULMEZ, O.
et al. 2001. The presence and extent of en-
dometriosis do not effect clinical pregnancy and implanta-
94. RICKES, D.
et al. 2002. Increased pregnancy rates after ultra-
tion rates in patients undergoing intracytoplasmic sperm
long postoperative therapy with gonadotropin-releasing
injection. Eur. J. Obstet. Gynecol. Reprod. Biol.
96: 102–
hormone analogs in patients with endometriosis. Fertil.
Steril.
78: 757–762.
Source: http://www.endpain.co.za/wp-content/uploads/2012/03/Endo-and-infertility-Ozkan_Ann-NY-Acad-Sci_2008.pdf
Technische Lieferbedingungen TL 6545-0007 Rucksack Combat First Responder B und C und Ersthelfer B Versorgungsnummer Versorgungsartikelname 6545-12-388-0503 RUCKSACK, ERSTE-HILFE-AUSSTATTUNG Procurement Types an keinen Hersteller gebunden Not tied to any manufacturer an einen Herstellerkreis gebunden durch Benutzungsrechtsvereinbarung
Credentialing as a Prescribing Psychologist in the Military: A Resource Manual Fairleigh Dickinson University M.S. Program in Clinical Psychopharmacology We are grateful to a number of individuals who contributed to the completion of this manual. The views expressed in this publication are those of the authors and do not reflect the official policy of position of the Department of the Army, Department of the Air Force, Department of the Navy, Department of Defense, Public Health Service, Indian Health Service, the United States Government, or any other agency for which the authors are employed. The final content is the sole responsibility of the Fairleigh Dickinson University M.S. Program in Clinical Psychopharmacology.